Portrait of a smiling child; the company labels it a patient portrayal Patient portrayal

Think it solvable.

Plus Therapeutics is now Cerenome (Nasdaq: CNSY, formerly PSTV): diagnostics, targeted therapeutics and patient data in one CNS oncology platform, as the company describes it.

CNSide®: Testing for CNS Cancer from Spinal Fluid

A laboratory-developed test that the company says detects, characterizes and monitors CNS cancer.

11,000+

CNSide tests performed since 2020, per the company

120+

U.S. cancer institutions where tests were performed, per the company

12

peer-reviewed publications evaluating CNSide in leptomeningeal metastases, per the company

Violet fibre-tract artwork on a coral ground, from the company's website
Company artwork

REYOBIQ™: Phase 2 Enrollment Complete

  • An investigational radiotherapeutic given by direct infusion into the tumor in recurrent glioblastoma.
    • 32 patients treated at the Phase 2 dose (34 planned)
    • Topline data expected mid‑2027
    • Not FDA-approved for any use

CNSide: Growing Payer Coverage

In-network agreements across commercial and Medicare Advantage plans, as the company reports.

~164M

Contracted covered lives

222

Tests billed in Q3 2026

$1.55M

Gross billings, Q3 2026, unaudited

A preliminary CMS pricing decision for the CNSide code was favorable; target effective date Jan 1, 2027, per the company.

Cerenome, Inc. NASDAQ: CNSY
More for investors

Forward-looking statements, including trial timing and results and CNSide coverage, reimbursement and billing, involve risks; actual results may differ materially. REYOBIQ is investigational and not FDA-approved. Billings are unaudited gross billings. See SEC filings for risk factors.